Ibex Investors’s Insmed INSM Stock Holding History

Ibex Investors’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,325	Closed	-$263K	–	220
2017 Q4	$263K	Buy	+8,325	New	+$246K	0.15%	89

Other funds holding INSM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Ibex Investors's INSM Position: Q1 2018 in Review

Ibex Investors sold out of Insmed (INSM) in Q1 2018, closing a stake of 8,325 shares — an estimated $263K sold.

Ibex Investors first reported a position in INSM in Q4 2017 and held it in 1 quarter. The position peaked at $263K in Q4 2017. 127 funds tracked by Wall St. Rank hold INSM as of Q1 2018.

Ibex Investors reported no remaining Insmed position as of Q1 2018 after selling out during the quarter.
Ibex Investors sold 8,325 Insmed shares in Q1 2018, an estimated $263K.
Ibex Investors first reported a position in Insmed in Q4 2017 and held it in 1 quarter.
Ibex Investors's Insmed position peaked at $263K in Q4 2017.
127 funds tracked by Wall St. Rank held Insmed as of Q1 2018.

Based on Ibex Investors's 13F filing for Q1 2018, filed 15 May 2018.